FASN and COVID-19: Approved medicines such as orlistat and metformin that act respectively on FASN and AMPK, and which are expected to inhibit virus replication and assembly or to promote gastrointestinal integrity and decrease deleterious systemic inflammation, merit serious consideration for clinical testing as anti-COVID-19 therapies (Figure 5).